| Ytd | -76.17% | |
| 1y | -95.02% |
| Open | 1.01 | Prev Close | 0.99 | Low | 1.00 | High | 1.01 | Mkt Cap | 953.68K |
| Vol | 13.66K | Avg Vol | 5.16M | EPS | -13.01 | P/E | -0.08 | Forward P/E | -2.57 |
| Beta | 3.68 | Short Ratio | 0.35 | Inst. Own | 10.83% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-23 | 50-d Avg | 1.54 | 200-d Avg | 4.73 | 1yr Est | 14.60 |
GOVX News
GeoVax Labs (GOVX) appears to have found support after losing some value lately, as indicated by the
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
GeoVax Labs, Inc. (GOVX) Discusses Building a Resilient Infectious Disease Preparedness Strategy Foc
Estee Lauder (EL) shares jumped 11.8% in pre-market trading after ending discussions with Puig. Othe
GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotech company, is trading higher on Wednesday as
GeoVax shares gain after the company highlighted its MVA vaccine platform's potential against Eb
https://geovax.com/investors/press-releases/geovax-comments-on-escalating-bundibugyo-ebola-outbreak-
GOVX stock pulls back premarket after an 80% rally as GeoVax Labs announces a $3M private placement,
https://x.com/PatentGrants/status/2056464996494880918
Liveramp Holdings Inc (NYSE: RAMP) rose in pre-market trading after being acquired by Publicis for $
GeoVax Labs (GOVX) might move higher on growing optimism about its earnings prospects, which is refl
Geovax Labs (NASDAQ:GOVX) reported quarterly losses of $(2.62) per share which beat the analyst cons
D. Boral Capital analyst Jason Kolbert maintains Geovax Labs (NASDAQ:GOVX) with a Buy and maintai
On January 9, 2026, GeoVax Labs, Inc. (the "Company" or "we") filed a Certificate of
GeoVax Labs Inc. (NASDAQ: GOVX - Get Free Report) was up 21.1% on Friday. The company traded as high
GeoVax Labs, Inc. ( GOVX ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants
GeoVax Labs (GOVX) might move higher on growing optimism about its earnings prospects, which is refl
GeoVax Labs Revenue Doubles in Q2
GeoVax Labs, Inc. (NASDAQ:GOVX ) Q2 2025 Earnings Conference Call July 28, 2025 4:30 PM ET Company P
GeoVax Labs, Inc. (NASDAQ:GOVX ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Par
D. Boral Capital lowered the firm's price target on GeoVax Labs to $14 from $18 and keeps a Buy rati
GeoVax Labs, Inc. (NASDAQ:GOVX ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company
Adds to Growing Portfolio of Intellectual Property Assets ATLANTA, Ga., Dec. 09, 2024 (GLOBE NEWSWIR
Known for their uncommonly pronounced risk/reward profile, penny stocks all too often entice investo
ATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company
GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript
Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVI
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs,
ATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology co
ATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology co